DualityBio Advances HER2 ADC Toward China Approval
SHANGHAI, China, April 9, 2026 DualityBio has announced that the China National Medical Products Administration (NMPA) has accepted the...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine solid tumors targeted therapy
SHANGHAI, China, April 9, 2026 DualityBio has announced that the China National Medical Products Administration (NMPA) has accepted the...
New York, March 27, 2026 OS Therapies has achieved a significant regulatory milestone by securing meetings with multiple global...
SECAUCUS, N.J. — March 12, 2026 Pierre Fabre Pharmaceuticals announced that the U.S. Food and Drug Administration has agreed...
February 24, 2026 — Foster City, CA & Redwood City, CA:Gilead Sciences, Inc. (Nasdaq: GILD) today revealed a definitive...
Rare Disease Biologic Advances Toward U.S. Approval – February 19, 2026 | Tarrytown, New York Regeneron Pharmaceuticals announced that...
Bala Cynwyd, Pa., September 29, 2025: Larimar Therapeutics announced positive new data from an ongoing long-term open-label study of...
CAMBRIDGE, Mass., Sept. 25, 2025 — Intellia Therapeutics announced positive longer-term Phase 1 data for its investigational CRISPR-based therapy...
